MediciNova, Inc. (NASDAQ:MNOV – Free Report) – Investment analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of MediciNova in a report issued on Friday, August 14th. HC Wainwright analyst L. Egana-Gorrono now forecasts that the biopharmaceutical company will earn ($0.28) per share for the year, down from their prior estimate of ($0.26). The consensus estimate for MediciNova’s current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for MediciNova’s Q4 2026 earnings at ($0.11) EPS and FY2027 earnings at ($0.45) EPS.
A number of other equities analysts have also recently issued reports on MNOV. Weiss Ratings cut shares of MediciNova from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of MediciNova in a research note on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.33.
MediciNova Price Performance
MNOV opened at $1.32 on Tuesday. The firm has a 50 day simple moving average of $1.34 and a 200 day simple moving average of $1.41. MediciNova has a fifty-two week low of $1.17 and a fifty-two week high of $1.96. The company has a market cap of $64.97 million, a price-to-earnings ratio of -6.29 and a beta of 0.63.
MediciNova (NASDAQ:MNOV – Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. MediciNova had a negative net margin of 1,168.70% and a negative return on equity of 26.51%. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.07 million.
Institutional Trading of MediciNova
A number of institutional investors and hedge funds have recently modified their holdings of the stock. StoneX Group Inc. acquired a new stake in shares of MediciNova in the 4th quarter valued at approximately $25,000. Goldman Sachs Group Inc. acquired a new position in MediciNova during the fourth quarter valued at approximately $35,000. Citadel Advisors LLC bought a new stake in MediciNova in the third quarter valued at approximately $92,000. Bank of New York Mellon Corp bought a new stake in MediciNova in the second quarter valued at approximately $103,000. Finally, Jane Street Group LLC bought a new stake in MediciNova in the fourth quarter valued at approximately $214,000. 9.90% of the stock is owned by institutional investors.
MediciNova Company Profile
MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.
The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.
Read More
- Five stocks we like better than MediciNova
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
